ClinicalTrials.gg
RecruitingNCT06163820BETTERUpdated Oct 13, 2026

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

A Phase 1/2 interventional study of Bevacizumab and Ipilimumab in Melanoma Brain Metastases, sponsored by Melanoma and Skin Cancer Trials Limited. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Melanoma and Skin Cancer Trials Limited · Phase 1/2, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 13, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 69 studies testing bevacizumab in Brain Neoplasms — 9 open to participants now, 11 under way, 5 of them phase 3. Bevacizumab · Brain Neoplasms.

Planned enrollment
33rd of 69
46 · median 41
Started
2026
with 2 others
Phase 1/2
8 of 69
1 open now
Primary completion
2028-01
later than 4 of 10 live
Registered
61st of 69
by date

Among the 69 studies testing bevacizumab in Brain Neoplasms, this one is the 33rd largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 1/2, reaches primary completion later than 4 of the 10 other live ones, and was the 61st registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

9 of the 69 studies testing bevacizumab in Brain Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing bevacizumab in Brain Neoplasms, or all of them as a file.
02

Study summary

Single arm phase I/II trial to evaluate the safety and efficacy of the combination of bevacizumab, with ipilimumab plus nivolumab, and hypofractionated stereotactic radiotherapy (hSRT) in patients with symptomatic melanoma brain metastases (MBM).

Read the detailed description

Despite significantly improved clinical outcomes for patients with metastatic melanoma, the subset of patients with symptomatic MBM still fare poorly with treatment. The current standard of care for this group of patients is combined immune checkpoint blockade with ipilimumab and nivolumab, with local treatment with neurosurgery or stereotactic radiotherapy added for larger/more symptomatic lesions.

Bevacizumab has demonstrated evidence in the treatment of cerebral radiation necrosis and in a case series, promising symptomatic benefit in this group of patients. With strong empirical evidence of the ability to wean patients from steroids, mechanistically, bevacizumab may augment anti-tumour immunity from immune checkpoint blockade.

Bevacizumab will be administered 7 days prior to combination immunotherapy with ipilimumab and nivolumab and then given 28 days later to coincide with the second cycle of ipilimumab and nivolumab and thereafter every 3 weeks. The starting dose will be 7.5mg/kg, given intravenously, for a total of four cycles, and is consistent with the existing literature on the treatment of cerebral radiation necrosis.

This trial aims to determine the safety of bevacizumab, in combination with ipilimumab, nivolumab and hSRT, defined as no more than 1/6 patients experiencing a bevacizumab-related SAE in the initial phase of the study.

03

Conditions studied

  • Melanoma Brain Metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Histologically (or cytologically) proven melanoma, with radiologically confirmed .
  • 2. Symptomatic from brain metastases at the time of study enrolment, or brain metastases that requires for the management of neurological symptoms.
  • 3. Intracranial lesions amenable to hypofractionated stereotactic radiotherapy. These are defined as all intracranial melanoma lesions greater or equal to 5 mm in diameter, all intracranial lesions that are causing symptoms, and all intracranial lesions located in the eloquent areas of the brain.
  • 4. World Health Organisation (WHO) performance status of 0 - 2
  • 5. At least one brain metastasis has to be symptomatic.
  • 6. Laboratory tests required: (Hb) ≥ 9.0 g/dL ≥ 1 x 109/L count ≥ 100 x 109/L Either: Serum ≤ 1.5 x (ULN) (Patients with isolated hyperbilirubinaemia due to Gilbert's syndrome are allowed.) Or: (ALT), aspartate aminotransferase (AST) ≤ 2.5 x (ULN) unless raised due to tumour in which case up to 5 x ULN is permissible ≥ 40 mL/min (Cockcroft-Gault or are acceptable)
  • 7. Age ≥ 18 years
  • 8. Able to provide informed written consent (signed and dated), attend trial site for study visits and be capable of co-operating with treatment and follow-up

Exclusion criteria

Exclusion Criteria:

  • 1. Prior radiotherapy to the brain
  • 2. Active concurrent requiring systemic anti-cancer therapy within the last 2 years. Patients with any malignancy treated with curative intent and no evidence of disease will be eligible for this trial.
  • 3. Prior systemic therapy for melanoma, unless given in the or adjuvant setting for extracranial disease only, completed more than >6 months prior to enrolment in this trial and if administered with radiological proof of the absence of
  • 4. Inability to undergo MRI of the brain
  • 5. Definitive . Patients with equivocal leptomeningeal disease may be included on the trial after discussion with CPI.
  • 6. Female patients who are pregnant or lactating. Patients who are able to become pregnant, must return a negative serum or urine pregnancy test before enrolment and agree to use two forms of (one effective form plus a barrier method) [oral, injected or implanted hormonal contraception and condom; intra-uterine device and condom; diaphragm with spermicidal gel and condom] or agree to sexual abstinence, effective from signing the consent form, throughout the trial and for six months after any treatment for melanoma, radiotherapy or immunotherapy, are considered eligible.
  • 7. Male patients with partners of (unless they agree to take measures not to father children by using a barrier method of contraception or to sexual abstinence effective from the first administration of bevacizumab, throughout the trial and for six months afterwards after treatment the end-of-trial visit. Men with partners of child-bearing potential must also be willing to ensure that their partner uses an effective method of contraception for the same duration for example, hormonal contraception, intrauterine device, diaphragm with spermicidal gel or sexual abstinence). Men with pregnant or lactating partners must be advised to use barrier method contraception to prevent exposure of the foetus or neonate. Abstinence is only considered to be an acceptable method of contraception when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  • 8. Haemorrhage encompassing >50% of any lesion that is >10 mm in diameter (excluding surrounding oedema). A modern susceptibility-sensitive MRI sequence such as SWI is mandatory.
  • 9. Brain metastases greater than 5 cm in maximal diameter
  • 10. Increasing dose for 48 hours prior to initiation of study therapy OR current dexamethasone-equivalent dose of >8 mg per day
  • 11. Major thoracic or abdominal surgery within 28 days prior to initiation of trial treatment
  • 12. Neurosurgery within 14 days prior to initiation of trial treatment
  • 13. Active or history of severe auto-immune disease requiring systemic anti-inflammatory therapy. Patients with well-controlled auto-immune diseases not requiring systemic anti-inflammatory therapy may be included after consultation with the CPI. Severe auto-immune respiratory disease will be excluded from the trial.
  • 14. History of inflammatory bowel disease
  • 15. Requirement for ongoing concurrent systemic therapy (other than corticosteroids).
  • 16. History of intra-abdominal inflammatory process within 6 months prior to initiation of trial treatment, including but not limited to peptic ulcer disease, diverticular disease or colitis.
  • 17. History of abdominal or trachea-oesophageal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to initiation of trial treatment
  • 18. History of intestinal obstruction and/or clinical signs or symptoms of gastrointestinal obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration, parenteral nutrition or tube feeding within 6 months prior to initiation of trial treatment
  • 19. Any Grade ≥3 haemorrhage or bleeding event within 28 days of trial treatment initiation. Patients presenting with haemorrhagic brain metastases that have been adequately treated with neurosurgery are not excluded under this criterion but remain subject to criterion 12 pertaining to timing of neurosurgery.
  • 20. Current use of full-dose anticoagulation or thrombolytic therapy within 10 days of initiation of trial treatment
  • 21. Evidence of bleeding diatheses or significant coagulopathy
  • 22. History of inadequately controlled arterial hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg despite maximal medical therapy); prior history of hypertensive crises or hypertensive encephalopathy
  • 23. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease, prior history of cardiac ischaemia or prior history of cardiac arrhythmia
  • 24. Concurrent participation in another interventional clinical trial or intention to do so. Concurrent participation in an observational trial is acceptable.
  • 25. Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Intervention

    Patients will receive the following: 1. Bevacizumab 7.5 mg/kg every 3 weeks for 4 cycles 2. Nivolumab 1 mg /kg + ipilimumab 3 mg/kg every 3 weeks for 4 cycles (induction phase) followed by nivolumab monotherapy at 480mg every 4 weeks (maintenance phase) 3. hSRT (24-27Gy/3# or 25-30Gy/5#)

    Drug: Bevacizumab · Drug: Ipilimumab · Drug: Nivolumab · Radiation: Hypofractionated stereotactic radiotherapy

Interventions

  • Bevacizumab is a humanised monoclonal antibody with molecular weight 167kD that inhibits all isoforms of the vascular endothelial growth factor (VEGF) and is produced from a Chinese hamster ovary mammalian system. It has high specificity for isoform-A and has a half-life of \~21 days.

    Also known as: Avastin

  • Ipilimumab is an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Ipilimumab is a recombinant human immunoglobulin monoclonal antibody that binds CTLA4 and blocks the interaction between CD80/86 and CTLA4.

    Also known as: Yervoy

  • Nivolumab ia an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Nivolumab is a fully human monoclonal IgG4 antibody targeting PD-1 which demonstrates activity across a range of tumours.

    Also known as: Opdivo

  • RadiationHypofractionated stereotactic radiotherapy

    Hypofractionated stereotactic radiotherapy (hSRT) will be delivered to previously untreated brain metastases in eligible participants. hSRT will be delivered to all symptomatic brain metastases, all brain metastases \>1 cm and all brain metastases located in eloquent areas of the brain. hSRT will be commenced after the first cycle of nivolumab plus ipilimumab and completed before the second cycle of nivolumab plus ipilimumab. hSRT should be commenced within 1 week from the planning MRI.

06

What researchers measure

Primary outcomes

  1. To determine the safety of bevacizumab, in combination with ipilimumab, nivolumab and hSRT

    Number of participants with bevacizumab-related SAEs. A dose-limiting toxicity rate of \<33% with a minimum of 3 patients treated will be considered safe.

    Time frame: 5 years

Secondary outcomes

  1. Determining the magnitude in reduction in prednisolone equivalent dose (relative to baseline dose)

    The combination of a strict patient diary of corticosteroid dose, volumetric analysis of oedema on paired MRI samples with Peripheral blood mononuclear cells (PBMCs) to delineate immune cell subsets will allow proof-of-mechanism to be demonstrated. Specifically, if the proposed combination demonstrates preliminary activity, we will be able to demonstrate that this activity corresponds to a decrease in steroid dose (diary) which is permissible due to reduced oedema (volumetric analysis), resulting in augmented antitumour immunity (as evidence by increased peripheral antitumour immune cells). Finally, the inclusion of a health-related quality of life (QoL) analysis in this early phase clinical trial, may demonstrate that the reduction in steroid dose is clinically meaningful to patients.

    Time frame: 2 years

  2. Intracranial clinical benefit

    The rate of intracranial clinical benefit, defined as the percentage of patients who had stable disease for at least 6 months after the initiation of treatment, complete response (CR), or partial response (PR)

    Time frame: 5 years

  3. Response rate

    The rate of overall response (defined as the rate of complete or partial response)

    Time frame: 5 years

  4. Progression-free survival

    The rate of intracranial, extracranial (systemic), and global progression-free survival (PFS)

    Time frame: 5 years

  5. Overall survival

    Overall survival

    Time frame: 5 years

  6. Volume of vasogenic oedema

    Determining the magnitude in reduction of the volume of vasogenic oedema around the brain metastases on MRI scan, after the administration of bevacizumab

    Time frame: 2 years

  7. To assess the patient-rated quality of life by the mean change from baseline quality of life scores [QLQ-C30] to the time of response, stable disease or progression.

    We will assess utility-based health-related quality of life (HRQoL) of the combination of bevacizumab, with ipilimumab plus nivolumab, and hSRT using scores from the EORTC QLQ-C30 instrument transformed to QLU-C10D algorithm at baseline and 6-weekly for 6 months, then 12 weekly thereafter to identify resultant improvements in patients' QoL. In addition, the utility indices will be used to estimate quality-adjusted life years (QALYs).

    Time frame: 2 years

Other outcomes

  1. To correlate anti-tumour activity with the detection of putative biomarkers of response/resistance in paired blood samples.

    Disease is measured according to the RECIST criteria (version 1.1). Imaging-based evaluation is preferred to evaluation by clinical examination when both methods have been used to assess the anti-tumour effect of a treatment. Overall response rate will be correlated to putative biomarkers.

    Time frame: 5 years

  2. Rate of cerebral radiation necrosis

    To assess the impact of upfront bevacizumab on rates of cerebral radiation necrosis compared to historical controls

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2028, 16 months after the start.

Of 51 non-industry phase 1/2 interventional studies under Brain Neoplasms, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 105. This study's planned 16 months is below that.

Counting every sponsor, half of 74 studies reached it within 85 months; a quarter within 49 and three quarters within 119.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start May 2025 → Aug 2026, primary completion Jan 2026 → Jan 2028 and completion Jan 2026 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Dec 11, 2023
StartActual
Aug 31, 2026was May 2025
Primary completionEst.
Jan 30, 2028was Jan 2026
CompletionEst.
Jan 30, 2030was Jan 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 31, 2025→Aug 31, 2026 (actual)
Oct 13, 2026
Primary completion
Jan 30, 2026→Jan 30, 2028
Oct 13, 2026
Study completion
Jan 30, 2026→Jan 30, 2030
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date May 31, 2025→Aug 31, 2026 (now actual)
    Primary completion Jan 30, 2026→Jan 30, 2028
    Study completion Jan 30, 2026→Jan 30, 2030
    + 4 other changes: verification date, criteria formatting, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06163820
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Responsible party
Sponsor
First posted
Dec 11, 2023
Start date
Aug 31, 2026
Primary completion
Jan 30, 2028 (estimated)
Completion
Jan 30, 2030 (estimated)
Last update
Oct 13, 2026

Study contacts

Katja Loewe
Contact
better@masc.org.au
+61399039022
Malaka Ameratunga
study chair · Monash University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Ipilimumab · Nivolumab

Start the discussion